# Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

> **NCT03947385** · PHASE1,PHASE2 · RECRUITING · sponsor: **IDEAYA Biosciences** · enrollment: 336 (estimated)

## Conditions studied

- Metastatic Uveal Melanoma
- Cutaneous Melanoma
- Colorectal Cancer
- Other Solid Tumors

## Interventions

- **DRUG:** IDE196
- **DRUG:** Binimetinib
- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT03947385
- **Lead sponsor:** IDEAYA Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-06-28
- **Primary completion:** 2027-01-29
- **Final completion:** 2027-06-15
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03947385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03947385, "Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03947385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*